The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03178149
Recruitment Status : Recruiting
First Posted : June 6, 2017
Last Update Posted : June 3, 2024
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine )

Tracking Information
First Submitted Date  ICMJE May 24, 2017
First Posted Date  ICMJE June 6, 2017
Last Update Posted Date June 3, 2024
Actual Study Start Date  ICMJE July 13, 2018
Estimated Primary Completion Date January 31, 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 8, 2020)
  • Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES) [ Time Frame: Up to 52 Weeks ]
    Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). An Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of ASP7317, the adjunct study medications and the study procedures, whether or not considered related to ASP7317, the adjunct study medications and the study procedures. A Treatment Emergent Adverse Event (TEAE) is defined as an AE beginning or worsening in severity after starting administration of the adjunct study medication.
  • Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs) [ Time Frame: Up to 52 Weeks ]
    An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly or birth defect or other medically important events.
  • Safety assessed by Adverse Events (AEs) of special interest [ Time Frame: Up to 52 Weeks ]
    AEs of special interest include: ectopic or proliferative cell growth (retinal pigment epithelial/epithelium (RPE) or non-RPE) with adverse clinical consequence; any new diagnosis of an immune-mediated disorder; any new cancer, irrespective of prior history; unexpected, clinically significant AEs possibly related to the cell transplant procedure; immunosuppressive therapy (IMT) or ASP7317 (e.g., graft failure or rejection).
  • Number of participants with cellular graft failure or rejection [ Time Frame: Up to 52 Weeks ]
    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.
  • Incidence of cellular graft failure or rejection [ Time Frame: Up to 52 Weeks ]
    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.
Original Primary Outcome Measures  ICMJE
 (submitted: June 5, 2017)
  • PoC only: Change from baseline in BCVA, measured by ETDRS method, average of assessments from weeks 4 to 26 [ Time Frame: Baseline and up to Week 26 ]
    Best corrected visual acuity (BCVA) will be measured by an assessor certified to use the early treatment of diabetic retinopathy study (ETDRS) method. Total number of letters read correctly will be reported.
  • Safety as assessed by Incidence, frequency and severity of adverse events (AEs) [ Time Frame: Up to 60 Months ]
    Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). Adverse event collection will begin upon the participant signing the informed consent.
  • Number of Participants with graft failure or rejection [ Time Frame: Up to 60 Months ]
    Evidence of graft failure or rejection will be assessed by BCVA, slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.
  • Number of Participants with clinically significant changes in laboratory tests [ Time Frame: Up to 26 Weeks ]
    An abnormality identified during a medical test will be defined as an AE only if the abnormality meets 1 of the following criteria: induces clinical signs or symptoms; requires active intervention; requires interruption or discontinuation of adjunct study medications; age-related eye disease studies (AREDS) lens grade increase from baseline by ≥ 1 grade; the abnormality or test value is clinically significant; visual acuity loss of ≥ 10 letters due to graft failure or rejection.
  • Number of Participants with clinically significant changes in blood pressure [ Time Frame: Up to 12 Weeks ]
    Clinically significant changes in blood pressure will be reported as moderate or severe.
  • Number of Participants with clinically significant changes in intraocular pressure (IOP) in each eye [ Time Frame: Up to 60 Months ]
    Intraocular pressure in both eyes will be measured by tonometry. Intraocular pressure should be measured after biomicroscopic examination and before pupil dilation approximately the same time of day, when possible.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 2, 2024)
  • Mean change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye [ Time Frame: Baseline, Weeks 26 and 52/End of Study (EOS) ]
    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).
  • Mean percent change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye [ Time Frame: Baseline, Weeks 26 and 52/End of Study (EOS) ]
    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).
  • Mean change from baseline in the square root transformation of Geographic Atrophy (GA) area in study eye and fellow eye [ Time Frame: Baseline, Weeks 26 and 52/End of Study (EOS) ]
    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).
  • Mean change from baseline in best corrected visual acuity (BCVA) score in study eye and fellow eye [ Time Frame: Baseline, Weeks 1, 4, 6, 8, 12, 16, 26 and 52/End of Study (EOS) ]
    BCVA will be measured by an assessor certified to use the Early Treatment of Diabetic Retinopathy Study (ETDRS) method. The BCVA score (in letter units) will be reported.
  • Mean change from baseline in mean sensitivity [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Mean sensitivity is the mean over all 3 point-wise sensitivity zones. Point-wise sensitivity will be estimated using imaging measures obtained across all 3 zones, treatment area, junctional and remote zone.
  • Mean change from baseline in point wise sensitivity (PWS) in treatment zone [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Point-wise sensitivity will be measured using sensitivity results obtained in the treatment zone as assessed by imaging criteria. Treatment zone in the study eye is defined as the area that corresponds to the subretinal bleb area identified by the day 0 fundus photograph.
  • Mean change from baseline in PWS in junctional zone [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Point-wise sensitivity will be measured using sensitivity results obtained in the junctional zone as assessed by imaging criteria. Junctional zone is defined as the non-atrophic retina adjacent to the GA area closest to the treatment zone.
  • Mean change from baseline in PWS in remote zone [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Point-wise sensitivity will be measured using sensitivity results obtained in the remote zone as assessed by imaging criteria. Remote zone is defined as retina outside and opposite to the treatment zone.
  • Mean change from baseline in number of scotomatous points [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Scotomatous points (loci) will be measured using imaging measures. The number of scotomatous points is the total number of points that were not seen (<0 dB loci).
  • Mean change from baseline in fixation stability (95% bivariate contour ellipse area (BCEA)) [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Fixation Stability will be measured using imaging measures obtained during the microperimetry testing session, categorized as stable, relatively unstable and unstable. Categorization of stability based on % of fixation points within a specified diameter circle centered in the gravitational center of all fixation points. Stable-More than 75% of fixation points located within 2 degree diameter circle. Relatively Unstable-Less than 75% of fixation points located within 2 degrees diameter circle, but more than 75% of fixation points located within 4 degree diameter circle. Unstable-Less than 75% of fixation points located within 4 degree diameter circle.
  • Mean change from baseline in distance of preferred retinal locus (PRL) from Fovea [ Time Frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS) ]
    Distance of PRL from Fovea will be measured using imaging measures obtained during the microperimetry testing session. Participant with central vision loss obtain visual information with a preferred eccentric retinal area for visual tasks because of their central scotoma. This area is called the preferred retinal locus.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 5, 2017)
  • PoC only: Change from baseline in BCVA at week 26 [ Time Frame: Baseline and Week 26 ]
    BCVA will be measured by an assessor certified to use the ETDRS method. Total number of letters read correctly will be reported.
  • PoC only: Proportion of participants with confirmed ≥ 15 letter improvement in BCVA at week 26 [ Time Frame: Baseline and Week 26 ]
    BCVA will be measured by an assessor certified to use the ETDRS method.
  • PoC only: Change from baseline in mean retinal sensitivity of the perilesional points by microperimetry at week 26 [ Time Frame: Baseline and Week 26 ]
    Microperimetry will be performed at all sites using a macular integrity assessment (MAIA) microperimeter.
  • PoC only: Change from baseline in area of definite decreased autofluorescence (DDAF) at week 26 [ Time Frame: Baseline and Week 26 ]
    DDAF will be assessed by Fundus Autofluorescence Photography (FAF). The image reading center will review the FAF images for area of DDAF and pattern of hyper autofluorescence around the DDAF.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Official Title  ICMJE A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
Brief Summary

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult.

ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD.

Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD.

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections.

There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317.

Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year).

During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.

Detailed Description The study consists of the following periods: Screening (up to 60 days) and the Study Period (52 weeks post treatment).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Age-Related Macular Degeneration
Intervention  ICMJE
  • Drug: ASP7317
    subretinal injection
  • Drug: tacrolimus
    oral
    Other Names:
    • FK506
    • Prograf®
  • Drug: trimethoprim-sulfamethoxazole
    oral
    Other Name: TMP/SMX
  • Drug: Acyclovir
    oral
  • Drug: Nystatin
    oral
Study Arms  ICMJE
  • Experimental: ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)

    Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Expansion cohorts (6 participants each) 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts.

    Sentinel dosing will be required for each dose level. After the first participant in Group 1 dose cohort is dosed and followed for 4 weeks, the Data Safety Monitoring Board (DSMB) will review the 4 week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated.

    The DSMB recommendation to progress to the next dosing cohort will be based on 4 week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection.

    Interventions:
    • Drug: ASP7317
    • Drug: tacrolimus
    • Drug: trimethoprim-sulfamethoxazole
    • Drug: Acyclovir
    • Drug: Nystatin
  • Experimental: ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)

    Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose).

    Expansion cohorts 5b and 6b (6 participants each) will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the DSMB recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose).

    Cohort 5 (medium cells/dose) dosing may begin after DSMB review of the 4 week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after DSMB review of 4 week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the DSMB review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection.

    Interventions:
    • Drug: ASP7317
    • Drug: tacrolimus
    • Drug: trimethoprim-sulfamethoxazole
    • Drug: Acyclovir
    • Drug: Nystatin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 2, 2024)
42
Original Estimated Enrollment  ICMJE
 (submitted: June 5, 2017)
150
Estimated Study Completion Date  ICMJE January 31, 2026
Estimated Primary Completion Date January 31, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

General Inclusion Criteria

  • Participant must be willing to take tacrolimus and willing to discontinue any medications that have a known strong interaction with tacrolimus.
  • Participant is able and willing to undertake all scheduled visits and assessments up to the week 52 visit.
  • Participant who is taking an antidepressant must be on a stable and effective dosage and must be willing to take it reliably for as long as it is required.
  • Participant must be willing and medically suitable to undergo monitored anesthesia care during the vitrectomy and subretinal injection.
  • Participant agrees to conform to local and institutional policies regarding active COVID-19 infections.
  • Participant agrees not to participate in another interventional study until the 52-week visit has been completed.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP)
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 52 weeks after investigational product (IP) administration.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 52 weeks after IP administration.
  • Female participant must not donate ova starting at first dose of IP and throughout the study period and for 52 weeks after IP administration.
  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 52 weeks after IP administration.
  • Male participant must not donate sperm during the treatment period and for 52 weeks after IP administration.
  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 52 weeks after IP administration.

Ocular Inclusion Criteria: Study Eye (Both Groups 1 and 2)

  • Participant has bilateral geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). GA is defined as sharply demarcated areas of loss of the retinal pigment epithelial/epithelium (RPE).
  • Participant has no known history of choroidal neovascularization (CNV) (wet AMD) in either eye prior to enrollment in the trial and no evidence of prior or active CNV with optical coherence tomographyangiography (OCT-A) or indocyanine green angiography (ICG-A), as assessed by the reading center.
  • Participant has absence of exudation as assessed by fluorescein angiography (FA) and spectral domain-optical coherence tomography (SD-OCT).
  • Participant has presence of either banded or diffuse hyperautofluorescence in the junctional zone of GA as assessed by the central reading center.
  • Participant has sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging.
  • Participant is pseudophakic.

Ocular Inclusion Criteria: Study Eye (Group 1 only)

  • For Cohort 1, the participant has a BCVA between light perception and </= 23 Early Treatment Diabetic Retinopathy study (ETDRS) letters at the screening visit. For Cohorts 2 and 3, the participant has a BCVA score between 20 (>/= 20/400) and 37 (</=20/200) ETDRS letters at the screening visit.
  • Participant has the total GA area </= 30.5 mm^2 (</=12 disc areas [DA]).

Ocular Inclusion Criteria: Study Eye (Group 2 only)

  • Participant has BCVA score between 38 (> 20/200) and 63 (</=20/63) ETDRS letters during the screening visit.
  • Participant has the total GA area of >/= 5.1 mm^2 and < 17.8 mm^2 (>/=2 and </=7 DA, respectively) and must reside completely within the fundus autofluorescence (FAF) imaging field (Field 2 to 30 degree image centered on the fovea). If GA is multifocal, at least 1 focal lesion must be >/= 2.5 mm^2 (>/=1 DA).
  • Participant has a difference in mean mesopic sensitivity </=2 dB between 2 tests at screening. If not </=2 dB, a third test may be conducted and mean values between the second and third assessments must be </=2 dB.

Exclusion Criteria:

General Exclusion Criteria

  • Participant has a history of recurrent varicella zoster virus (VZV) infection or a clinical diagnosis of VZV infection within 4 weeks of the baseline visit or positive anti-VZV immunoglobulin M (IgM). Being positive for immunoglobulin G (IgG), indicative of a past infection (or vaccination), is not an exclusionary criterion.
  • Participant has a history of recurrent cytomegalovirus (CMV) infection or a clinical diagnosis of CMV infection within 4 weeks of the baseline visit or positive anti-CMV IgM. Being positive for IgG, indicative of a past infection, is not an exclusionary criterion.
  • Participant has a positive tuberculosis (TB) test during the screening period by an interferon gamma release assay (e.g., QuantiFERON) within the 6 months prior to the screening. If a participant has tested negative for TB within the 6 months prior to the screening visit, retesting is not required unless clinically indicated.
  • Participant has a history or suspected active infection of toxoplasmosis or presence of elevated immunoglobulin M (IgM) toxoplasmosis titer within 4 weeks of the baseline visit.
  • Participant has an active infection (ocular or non-ocular) requiring the prolonged or chronic use of antimicrobial or anti-infective agents.
  • Participant has a current malignancy or history of malignancy within the past 5 years, except non-metastatic basal or squamous cell carcinoma or keratoacanthoma or Bowen's disease or carcinoma-in-situ of the cervix that has been successfully treated.
  • Participant has a history of a solid organ or bone marrow transplant.
  • Participant has any condition that would prohibit the use of systemic immunosuppression with tacrolimus.
  • Participant is receiving or has received any immunosuppressive therapy (IMT) (other than topical, inhaled or low dose systemic corticosteroid use not exceeding 7.5 mg of prednisone daily [or equivalent]) within 6 weeks or 5 plasma half-lives, whichever is longer, prior to the administration of adjunct study medications.
  • Participant has a history of myocardial infarction in previous 12 months and whose disease is either unstable and/or symptomatic (e.g., angina, dyspnea, etc.).
  • Participant has electrocardiogram (ECG) results that are clinically significant and could either jeopardize the safety of the participant, impact the participant's ability to comply with study visit schedule or impact the validity of the study results. Participants with a mean Fridericia-corrected QT interval of > 430 ms (for males) and > 450 ms (for females) at screening must be cleared by a cardiologist prior to the baseline visit.
  • Participant has a study day diastolic blood pressure > 95 mmHg, at either the screening or baseline visit. Study day blood pressure is defined as the average of the second and third readings at a study visit. If the study day blood pressure exceeds the limits, 1 additional triplicate can be taken.
  • Participant has an estimated glomerular filtration rate (eGFR) of </= 45 mL/min, calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) equation.
  • Participant has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma- glutamyltransferase (GGT) and total bilirubin (TBL) >/= 2 times the upper limit of normal (ULN).
  • Participant has severe anemia (hemoglobin < 9 g/dL [male] or hemoglobin < 8 g/dL [female]), leucopenia (white blood cell count < 2500/mm^3), thrombocytopenia (platelet count < 80000/mm^3) or polycythemia (hematocrit > 54% [male] or hematocrit > 49% [female]).
  • Participant has a hemoglobin A1c > 8.5%.
  • Participant has a clinically significant coagulopathy (i.e., activated partial thromboplastin time [aPTT] >/= 1.5 times the ULN and/or prothrombin time adjusted for the international normalized ratio [PT-INR] >/=2.0).
  • Participant has serology results indicative of having syphilis, Lyme disease, human immunodeficiency virus infection or active infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or varicella-zoster virus (VZV).
  • Participant has a history of familial adenomatous polyposis or inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
  • Participant has a history of allergic reaction to mydriatics or fluorescein.
  • Participant has a history of gene therapy or cell transplant therapy, including ASP7316, in a prior clinical study.
  • Participant has participated in any studies of an investigational drug or procedure (excluding vitamins and minerals for AMD studies) within 12 weeks prior to the screening visit, except as noted in below criterion.
  • Participant has participated with the study eye in any trial of a now FDA-approved complement inhibitor and/or has received an FDA approved complement inhibitor injection in the study eye within 24 weeks of the screening visit. After a washout period of 24 or more weeks, participants previously treated with a complement inhibitor will be eligible for participation, but participants will not be allowed to resume receiving any approved or investigational complement inhibitor in the study eye until the completion of the 52-week follow up period of the A7317-CL-0003 trial. Use of an FDA-approved complement inhibitor in the fellow, non-study eye is allowable.
  • Participant is unwilling to discontinue or avoid any CYP3A4 inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St John's Wort) or participant is unwilling to discontinue or avoid protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir), direct Factor Xa inhibitors, direct thrombin inhibitors, verapamil, diltiazem or erythromycin while taking tacrolimus.
  • Participant has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, opiates, cocaine, phencyclidine and methadone), unless the drug is taken for a documented medical condition and under the supervision of a physician.

Ocular Exclusion Criteria - Study Eye

  • Participant has macular degeneration due to causes other than AMD (e.g., Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.)
  • Participant has developed CNV (wet AMD), also known as exudative AMD in either eye.
  • Participant has foveal sparing as determined by the presence of potentially viable photoreceptors, as evidenced by presence of ellipsoid zone (EZ) </= 250 microns from the foveal center, based on reading center assessments at the screening visit.
  • Participant has a history of vitrectomy or submacular surgery, or any surgical intervention for AMD. Participants with a history of non-AMD-related surgical interventions (other than vitrectomy and submacular surgery) are potentially eligible if they meet all other inclusion/exclusion criteria.
  • Participant has prior treatment with photodynamic therapy (e.g., Visudyne®), intraocular external-beam radiation therapy or transpupillary thermotherapy.
  • Participant has a history of previous laser photocoagulation for choroidal neovascularization (CNV), diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.
  • Participant has a history of intravitreal drug delivery (e.g., anti-VEGF drugs, intravitreal corticosteroid injection or device implantation) in either eye within 1 year prior to the screening visit for any condition other than AMD. Use of anti-VEGF injections at any point in time due to prior history of CNV (wet AMD) is not permitted as prior history of wet AMD is an exclusionary criterion.
  • Participant has an abnormality of vitreoretinal interface (e.g., tractional epiretinal membrane (ERM)), which can interfere with measurement of macular thickness or with the potential for macular structural damage.
  • Participant has a history of cystoid macular edema, retinal vascular occlusion, central serous chorioretinopathy, macular hole or retinoschisis.
  • Participant has peripheral holes or other peripheral retinal lesions that are considered of rhegmatogenous potential (that is, with a risk of causing retinal detachment).
  • Participant has active or history of intraocular inflammation such as uveitis, chorioretinitis and optic neuropathy (other than glaucoma).
  • Participant has presence of an ocular toxoplasmosis scar.
  • Participant has nevus of Ota (oculodermal melanocytosis), a pigmented choroidal lesion showing characteristics associated with high risk of malignancy (e.g., elevated lesion) or a choroidal nevus in the macula.
  • Participant has pathologic myopia defined as a spherical equivalent of > 8.00 diopters or axial length > 28 mm at the screening visit, or myopic macular degeneration or posterior staphyloma.
  • Participant has glaucoma with uncontrolled intraocular pressure (IOP) (defined as IOP > 30 mmHg despite treatment with anti-glaucoma medication) or is using more than 2 agents to control IOP or a history of glaucoma-filtering surgery.
  • Participant has a history of corneal transplantation.
  • Participant has monocular vision; no light perception in the fellow eye or anophthalmic in the fellow eye.
  • Participant has a contraindication to pupil dilation.
  • Participant has any other ocular condition that can interfere with the assessment of imaging data.
  • ADAPTIVE OPTICS RETINAL IMAGING SUBSTUDY ONLY: Either eye with GA area >/=7 DA, or has photosensitivity, or is at high risk for light hazard, or has a multifocal intraocular lens, or has an optical zone < 5 mm in diameter, or has capsulorhexis smaller than 5 mm. Note: this is not an exclusion criterion for the participant from the study, but only an exclusion of the participant's eye(s) from Adaptive Optics Retinal Imaging substudy.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 50 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Astellas Institute for Regenerative Medicine 800-888-7704 astellas.registration@astellas.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03178149
Other Study ID Numbers  ICMJE 7317-CL-0003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Current Responsible Party Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine )
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Astellas Institute for Regenerative Medicine
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Astellas Pharma Global Development, Inc.
PRS Account Astellas Pharma Inc
Verification Date May 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP